These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 34050793)

  • 21. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center.
    Chen F; Zuo Y; Li S; Shi J; Wang G; Shu X
    Respir Med; 2019 Aug; 155():127-132. PubMed ID: 31344662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 23. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
    Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
    Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
    Yen TH; Tseng CW; Wang KL; Fu PK
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.
    Shi Y; You H; Liu C; Qiu Y; Lv C; Zhu Y; Xu L; Wang F; Zhang M; Tan W
    Orphanet J Rare Dis; 2024 Apr; 19(1):170. PubMed ID: 38637830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report.
    Kodera H; Hirano R; Akiyama M; Matsumoto Y
    Mod Rheumatol Case Rep; 2024 Jul; 8(2):291-295. PubMed ID: 38753322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
    Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
    BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.
    Chen X; Zhang L; Jin Q; Lu X; Lei J; Peng Q; Wang G; Ge Y
    Front Immunol; 2022; 13():987841. PubMed ID: 36110863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
    Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
    J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
    Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
    Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical manifestations and outcome of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody positive patients with interstitial lung disease.
    Feng L; Wang H; Zhao Y; Zhao T; Zhang J; Huang F; Zhu J
    Clin Exp Rheumatol; 2022 Jan; 40(1):97-103. PubMed ID: 33635220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
    Li Y; Liu X; Tian M; Zou R; Gao Y; Huang M; Zhou K; Cao M; Cai H
    Clin Respir J; 2023 Jun; 17(6):507-515. PubMed ID: 37041007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T
    Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
    Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.